Entrada Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Entrada Therapeutics, Inc. (TRDA) on June 10, 2026. The report details the results of the Company's 2026 Annual Meeting of Stockholders, held virtually on the same date. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder votes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
As of the record date (April 13, 2026), 38,820,616 shares of Common Stock were outstanding. A quorum was established with 33,190,234 shares present or represented. Stockholders approved the following matters:
- Proposal 1 (Director Election): Peter S. Kim, Ph.D., and Bernhardt Zeiher, M.D., were elected as Class II directors to serve until the 2029 annual meeting.
- Proposal 2 (Auditor Ratification): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
- Proposal 3 (Equity Plan Amendment): Stockholders approved Amendment No. 1 to the 2021 Stock Option and Incentive Plan.
- Proposal 4 (ESPP Amendment): Stockholders approved Amendment No. 1 to the 2021 Employee Stock Purchase Plan.
The amendments to the 2021 Plan and 2021 ESPP modify the "evergreen" provision. The change ensures that outstanding pre-funded warrants are included in the calculation of outstanding common stock when determining the annual increase in shares available for issuance.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, or contingencies. The primary focus is the administrative completion of the Annual Meeting and the approval of equity plan amendments.
Key Facts for Investor Verification
- Verify the impact of the approved equity plan amendments on future share dilution, specifically regarding the inclusion of pre-funded warrants in the evergreen formula.
- Review the full text of Amendment No. 1 to the 2021 Stock Option and Incentive Plan (Exhibit 10.1) and Amendment No. 1 to the 2021 ESPP (Exhibit 10.2) for specific terms.
- Note the significant number of broker non-votes (8,930,773) on the director election and equity plan proposals, indicating shares held by brokers that were not voted on these discretionary matters.
- Confirm the tenure of the newly elected directors, Peter S. Kim and Bernhardt Zeiher, extending through the 2029 annual meeting.